On the benefits of sin

References

• Forthal DN, Landucci G, Daar ES. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 2001; 75:6953 - 61; http://dx.doi.org/10.1128/JVI.75.15.6953-6961.2001; PMID: 11435575
   PubMed Web of Science ®Google Scholar
• Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003; 100:4144 - 9; http://dx.doi.org/10.1073/pnas.0630530100; PMID: 12644702
   PubMed Web of Science ®Google Scholar
• Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307 - 12; http://dx.doi.org/10.1038/nature01470; PMID: 12646921
   PubMed Web of Science ®Google Scholar
• Chung AW, Isitman G, Navis M, Kramski M, Center RJ, Kent SJ, et al. Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci U S A 2011; 108:7505 - 10; http://dx.doi.org/10.1073/pnas.1016048108; PMID: 21502492
   PubMed Web of Science ®Google Scholar
• Köhler H, Müller S, Nara PL. Deceptive imprinting in the immune response against HIV-1. Immunol Today 1994; 15:475 - 8; http://dx.doi.org/10.1016/0167-5699(94)90192-9; PMID: 7945772
   PubMedGoogle Scholar
• Kohler H, Goudsmit J, Nara P. Clonal dominance: cause for a limited and failing immune response to HIV-1 infection and vaccination. J Acquir Immune Defic Syndr 1992; 5:1158 - 68; PMID: 1403647
   PubMed Web of Science ®Google Scholar
• Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 2011; 11:532 - 43; http://dx.doi.org/10.1038/nri3014; PMID: 21760609
   PubMed Web of Science ®Google Scholar
• Choi YS, Baek YH, Kang W, Nam SJ, Lee J, You S, et al. Reduced antibody responses to the pandemic (H1N1) 2009 vaccine after recent seasonal influenza vaccination. Clin Vaccine Immunol 2011; 18:1519 - 23; http://dx.doi.org/10.1128/CVI.05053-11; PMID: 21813667
   PubMed Web of Science ®Google Scholar
• Gao Y, Wen Z, Dong K, Zhong G, Wang X, Bu Z, et al. Characterization of immune responses induced by immunization with the HA DNA vaccines of two antigenically distinctive H5N1 HPAIV isolates. PLoS One 2012; 7:e41332; http://dx.doi.org/10.1371/journal.pone.0041332; PMID: 22859976
   PubMedGoogle Scholar
• Kim JH, Skountzou I, Compans R, Jacob J. Original antigenic sin responses to influenza viruses. J Immunol 2009; 183:3294 - 301; http://dx.doi.org/10.4049/jimmunol.0900398; PMID: 19648276
   PubMed Web of Science ®Google Scholar
• Kucharski AJ, Gog JR. The role of social contacts and original antigenic sin in shaping the age pattern of immunity to seasonal influenza. PLoS Comput Biol 2012; 8:e1002741; http://dx.doi.org/10.1371/journal.pcbi.1002741; PMID: 23133346
   PubMed Web of Science ®Google Scholar
• Midgley CM, Bajwa-Joseph M, Vasanawathana S, Limpitikul W, Wills B, Flanagan A, et al. An in-depth analysis of original antigenic sin in dengue virus infection. J Virol 2011; 85:410 - 21; http://dx.doi.org/10.1128/JVI.01826-10; PMID: 20980526
   PubMed Web of Science ®Google Scholar
• Bende RJ, van Maldegem F, Triesscheijn M, Wormhoudt TA, Guijt R, van Noesel CJ. Germinal centers in human lymph nodes contain reactivated memory B cells. J Exp Med 2007; 204:2655 - 65; http://dx.doi.org/10.1084/jem.20071006; PMID: 17938234
   PubMed Web of Science ®Google Scholar
• Rada C, Gupta SK, Gherardi E, Milstein C. Mutation and selection during the secondary response to 2-phenyloxazolone. Proc Natl Acad Sci U S A 1991; 88:5508 - 12; http://dx.doi.org/10.1073/pnas.88.13.5508; PMID: 1905811
   PubMedGoogle Scholar
• Breden F, Lepik C, Longo NS, Montero M, Lipsky PE, Scott JK. Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. PLoS One 2011; 6:e16857; http://dx.doi.org/10.1371/journal.pone.0016857; PMID: 21479208
   PubMed Web of Science ®Google Scholar
• Locher CP, Grant RM, Collisson EA, Reyes-Terán G, Elbeik T, Kahn JO, et al. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination. AIDS Res Hum Retroviruses 1999; 15:1685 - 9; http://dx.doi.org/10.1089/088922299309720; PMID: 10606091
   PubMedGoogle Scholar
• Müller S, Wang H, Silverman GJ, Bramlet G, Haigwood N, Köhler H. B-cell abnormalities in AIDS: stable and clonally-restricted antibody response in HIV-1 infection. Scand J Immunol 1993; 38:327 - 34; http://dx.doi.org/10.1111/j.1365-3083.1993.tb01734.x; PMID: 7692591
   PubMedGoogle Scholar
• Berberian L, Valles-Ayoub Y, Sun N, Martinez-Maza O, Braun J. A VH clonal deficit in human immunodeficiency virus-positive individuals reflects a B-cell maturational arrest. Blood 1991; 78:175 - 9; PMID: 2070051
   PubMed Web of Science ®Google Scholar
• Li L, Wang XH, Banerjee S, Volsky B, Williams C, Virland D, et al. Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infected subject. PLoS One 2012; 7:e39534; http://dx.doi.org/10.1371/journal.pone.0039534; PMID: 22761815
   PubMedGoogle Scholar
• Parsons MS, Rouleau D, Routy JP, LeBlanc R, Grant MD, Bernard NF. Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire. AIDS 2011; 25:1249 - 64; http://dx.doi.org/10.1097/QAD.0b013e328347f9fa; PMID: 21516028
   PubMedGoogle Scholar
• Wang H, Müller S, Zolla-Pazner S, Köhler H. Human monoclonal and polyclonal anti-human immunodeficiency virus-1 antibodies share a common clonotypic specificity. Eur J Immunol 1992; 22:1749 - 55; http://dx.doi.org/10.1002/eji.1830220713; PMID: 1378015
   PubMedGoogle Scholar
• Parsons MS, Center RJ, Routy JP, Rouleau D, Leblanc R, Wainberg MA, et al. Antibody Responses to Human Immunodeficiency Virus Envelope from Infections with Multiple Subtypes Utilize the 1F7-Idiotypic Repertoire. AIDS Res Hum Retroviruses 2013; http://dx.doi.org/10.1089/aid.2012.0094; PMID: 23265432
   PubMedGoogle Scholar
• Muller S, Grant MD. Anti-idiotypic antibodies and idiotypic T cell selection in HIV infection. In: Shoenfeld Y, Kennedy RC, Ferrone S, eds. Idiotypes in medicine autoimmunity, infection, and cancer. Amsterdam: Elsevier, 1997: 381-394.
   Google Scholar
• Wang QL, Wang HT, Blalock E, Müller S, Köhler H. Identification of an idiotypic peptide recognized by autoantibodies in human immunodeficiency virus-1-infected individuals. J Clin Invest 1995; 96:775 - 80; http://dx.doi.org/10.1172/JCI118122; PMID: 7635971
   PubMedGoogle Scholar
• Müller S, Wang HT, Kaveri SV, Chattopadhyay S, Köhler H. Generation and specificity of monoclonal anti-idiotypic antibodies against human HIV-specific antibodies. I. Cross-reacting idiotopes are expressed in subpopulations of HIV-infected individuals. J Immunol 1991; 147:933 - 41; PMID: 1861082
   PubMed Web of Science ®Google Scholar
• Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris) 1974; 125C:373 - 89; PMID: 4142565
   PubMedGoogle Scholar
• Köhler H, Kaveri S, Kieber-Emmons T, Morrow WJ, Müller S, Raychaudhuri S. Idiotypic networks and nature of molecular mimicry: an overview. Methods Enzymol 1989; 178:3 - 35; http://dx.doi.org/10.1016/0076-6879(89)78003-4; PMID: 2481210
   PubMed Web of Science ®Google Scholar
• Müller S, Margolin DH, Min G. An HIV-1 infection-related idiotype/clonotype (1F7) is expressed on antibodies directed to envelope glycoprotein in simian immunodeficiency virus- and chimeric simian/human immunodeficiency virus-infected rhesus monkeys. Hybridoma 1997; 16:17 - 21; http://dx.doi.org/10.1089/hyb.1997.16.17; PMID: 9085123
   PubMedGoogle Scholar
• Muller S, Schwartz D, Wang H-T, Wang Q, Kohler H, Pahwa S, et al. Expression of an HIV-1 infection-related idiotype/clonotype in antibodies directed to envelope glycoprotein gp120 of HIV-1: Early and concomitant idiotype increase in antibodies against the homologous vaccine strain. Vaccine Research 1995; 4:71 - 85
   Google Scholar
• Davtyan TK, Hovsepyan MP, Mkhitaryan LM, Hakobyan GS, Brazil A, Barrett L, et al. The 1F7 idiotype is selectively expressed on CD5+ B cells and elevated in chronic hepatitis C virus infection. Immunol Cell Biol 2009; 87:457 - 63; http://dx.doi.org/10.1038/icb.2009.18; PMID: 19333248
   PubMedGoogle Scholar
• Grant MD. Antibody convergence along a common idiotypic axis in immunodeficiency virus and hepatitis C virus infections. J Med Virol 2002; 66:13 - 21; http://dx.doi.org/10.1002/jmv.2105; PMID: 11748653
   PubMedGoogle Scholar
• Hoffmann GW, Muller S, Kohler H. Towards an HIV vaccine based on immune network theory. Curr Trends Immunol 2012; 13:69 - 79
   Google Scholar
• Muller S, Margolin DH, Min G, Lou D, Nara P, Axthelm MK, et al. Stimulation of antiviral antibody response in SHIV-IIIB-infected macaques. Scand J Immunol 2001; 54:383 - 95; http://dx.doi.org/10.1046/j.1365-3083.2001.00982.x; PMID: 11555405
   PubMedGoogle Scholar
• Müller S, Margolin DH, Nara PL, Alvord WG, Köhler H. Stimulation of HIV-1-neutralizing antibodies in simian HIV-IIIB-infected macaques. Proc Natl Acad Sci U S A 1998; 95:276 - 81; http://dx.doi.org/10.1073/pnas.95.1.276; PMID: 9419366
   PubMedGoogle Scholar
• Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010; 329:811 - 7; http://dx.doi.org/10.1126/science.1192819; PMID: 20616231
   PubMed Web of Science ®Google Scholar
• Doria-Rose NA, Klein RM, Daniels MG, O’Dell S, Nason M, Lapedes A, et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol 2010; 84:1631 - 6; http://dx.doi.org/10.1128/JVI.01482-09; PMID: 19923174
   PubMed Web of Science ®Google Scholar
• Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, et al, CAPRISA002 Study Team. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 2011; 85:4828 - 40; http://dx.doi.org/10.1128/JVI.00198-11; PMID: 21389135
   PubMed Web of Science ®Google Scholar
• Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003; 300:2065 - 71; http://dx.doi.org/10.1126/science.1083182; PMID: 12829775
   PubMed Web of Science ®Google Scholar
• Zwick MB, Jensen R, Church S, Wang M, Stiegler G, Kunert R, et al. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 2005; 79:1252 - 61; http://dx.doi.org/10.1128/JVI.79.2.1252-1261.2005; PMID: 15613352
   PubMed Web of Science ®Google Scholar
• Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al, Protocol G Principal Investigators. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326:285 - 9; http://dx.doi.org/10.1126/science.1178746; PMID: 19729618
   PubMed Web of Science ®Google Scholar
• Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75:8340 - 7; http://dx.doi.org/10.1128/JVI.75.17.8340-8347.2001; PMID: 11483779
   PubMed Web of Science ®Google Scholar
• Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003; 9:343 - 6; http://dx.doi.org/10.1038/nm833; PMID: 12579198
   PubMed Web of Science ®Google Scholar
• Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A 2011; 108:11181 - 6; http://dx.doi.org/10.1073/pnas.1103012108; PMID: 21690411
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009; 5:e1000433; http://dx.doi.org/10.1371/journal.ppat.1000433; PMID: 19436712
   PubMed Web of Science ®Google Scholar
• Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012; 481:81 - 4; http://dx.doi.org/10.1038/nature10660; PMID: 22139420
   PubMed Web of Science ®Google Scholar
• Euler Z, Schuitemaker H. Cross-reactive broadly neutralizing antibodies: timing is everything. Front Immunol 2012; 3:215; http://dx.doi.org/10.3389/fimmu.2012.00215; PMID: 22833745
   PubMedGoogle Scholar
• Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, Wrin T, et al. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis 2010; 201:1045 - 53; http://dx.doi.org/10.1086/651144; PMID: 20170371
   PubMed Web of Science ®Google Scholar
• van Gils MJ, Edo-Matas D, Bowles EJ, Burger JA, Stewart-Jones GB, Schuitemaker H. Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum. J Virol 2011; 85:8443 - 8; http://dx.doi.org/10.1128/JVI.05214-11; PMID: 21653664
   PubMedGoogle Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al, MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209 - 20; http://dx.doi.org/10.1056/NEJMoa0908492; PMID: 19843557
   PubMed Web of Science ®Google Scholar
• Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, Thongcharoen P, et al, Thai AIDS Vaccine Evaluation Group, Thailand. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 2005; 23:2522 - 9; http://dx.doi.org/10.1016/j.vaccine.2004.10.028; PMID: 15752839
   PubMed Web of Science ®Google Scholar
• Wren L, Kent SJ. HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity. Hum Vaccin 2011; 7:466 - 73; http://dx.doi.org/10.4161/hv.7.4.14123; PMID: 21389779
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101 - 4; http://dx.doi.org/10.1038/nature06106; PMID: 17805298
   PubMed Web of Science ®Google Scholar
• Hoffmann GW. Co-selection in immune network theory and in AIDS pathogenesis. Immunol Cell Biol 1994; 72:338 - 46; http://dx.doi.org/10.1038/icb.1994.51; PMID: 7806268
   PubMedGoogle Scholar
• Behn U. Idiotypic networks: toward a renaissance?. Immunol Rev 2007; 216:142 - 52; PMID: 17367340
   PubMed Web of Science ®Google Scholar
• Roitt IM, Cooke A, Male DK, Hay FC, Guarnotta G, Lydyard PM, et al. Idiotypic networks and their possible exploitation for manipulation of the immune response. Lancet 1981; 1:1041 - 5; http://dx.doi.org/10.1016/S0140-6736(81)92199-1; PMID: 6164887
   PubMed Web of Science ®Google Scholar
• Eichmann K. Idiotype suppression. I. Influence of the dose and of the effector functions of anti-idiotypic antibody on the production of an idiotype. Eur J Immunol 1974; 4:296 - 302; http://dx.doi.org/10.1002/eji.1830040413; PMID: 4546826
   PubMedGoogle Scholar
• Geha RS. Presence of auto-anti-idiotypic antibody during the normal human immune response to tetanus toxoid antigen. J Immunol 1982; 129:139 - 44; PMID: 7086128
   PubMed Web of Science ®Google Scholar
• Szewczuk MR. Selective suppression by auto-anti-idiotypic antibody of B-cell idiotype repertoires generated after stimulation with the same hapten on T-dependent and T-independent carriers. Cell Immunol 1983; 82:282 - 91; http://dx.doi.org/10.1016/0008-8749(83)90162-4; PMID: 6360382
   PubMedGoogle Scholar
• Zanetti M, Glotz D, Rogers J. Perturbation of the autoimmune network. II. Immunization with isologous idiotype induces auto-anti-idiotypic antibodies and suppresses the autoantibody response elicited by antigen: a serologic and cellular analysis. J Immunol 1986; 137:3140 - 6; PMID: 3490512
   PubMed Web of Science ®Google Scholar
• Klasse PJ, Sanders RW, Cerutti A, Moore JP. How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?. AIDS Res Hum Retroviruses 2012; 28:1 - 15; http://dx.doi.org/10.1089/aid.2011.0053; PMID: 21495876
   PubMed Web of Science ®Google Scholar
• Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, et al, MOPH TAVEG Collaboration. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses 2012; 28:1444 - 57; http://dx.doi.org/10.1089/aid.2012.0103; PMID: 23035746
   PubMed Web of Science ®Google Scholar
• Haynes BF, Moody MA, Liao HX, Verkoczy L, Tomaras GD. B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. Trends Mol Med 2011; 17:108 - 16; http://dx.doi.org/10.1016/j.molmed.2010.10.008; PMID: 21112250
   PubMed Web of Science ®Google Scholar
• Reynolds MR, Weiler AM, Weisgrau KL, Piaskowski SM, Furlott JR, Weinfurter JT, et al. Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med 2008; 205:2537 - 50; http://dx.doi.org/10.1084/jem.20081524; PMID: 18838548
   PubMed Web of Science ®Google Scholar
• Sugimoto C, Watanabe S, Naruse T, Kajiwara E, Shiino T, Umano N, et al. Protection of macaques with diverse MHC genotypes against a heterologous SIV by vaccination with a deglycosylated live-attenuated SIV. PLoS One 2010; 5:e11678; http://dx.doi.org/10.1371/journal.pone.0011678; PMID: 20652030
   PubMedGoogle Scholar
• Gundlach BR, Lewis MG, Sopper S, Schnell T, Sodroski J, Stahl-Hennig C, et al. Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain. J Virol 2000; 74:3537 - 42; http://dx.doi.org/10.1128/JVI.74.8.3537-3542.2000; PMID: 10729127
   PubMedGoogle Scholar
• Hoffmann GW, Kion TA, Grant MD. An idiotypic network model of AIDS immunopathogenesis. Proc Natl Acad Sci U S A 1991; 88:3060 - 4; http://dx.doi.org/10.1073/pnas.88.8.3060; PMID: 1901653
   PubMed Web of Science ®Google Scholar
• Müller C, Kukel S, Bauer R. Antibodies against CD4+ lymphocytes in plasma of HIV-infected patients are related to CD4 cell depletion in vivo. Immunol Lett 1994; 41:163 - 7; http://dx.doi.org/10.1016/0165-2478(94)90127-9; PMID: 8002032
   PubMedGoogle Scholar
• Chams V, Jouault T, Fenouillet E, Gluckman JC, Klatzmann D. Detection of anti-CD4 autoantibodies in the sera of HIV-infected patients using recombinant soluble CD4 molecules. AIDS 1988; 2:353 - 61; http://dx.doi.org/10.1097/00002030-198810000-00004; PMID: 3146263
   PubMedGoogle Scholar
• Süsal C, Hoffman GW, Daniel V, Grant M, Opelz G. Complementarities and network interactions in AIDS. J Autoimmun 1993; 6:601 - 10; http://dx.doi.org/10.1006/jaut.1993.1049; PMID: 8240663
   PubMedGoogle Scholar
• Wang X, Zhang A, Liu Y, Chen S, Feng Z, Shang W, et al. Anti-idiotypic antibody specific to GAD65 autoantibody prevents type 1 diabetes in the NOD mouse. PLoS One 2012; 7:e32515; http://dx.doi.org/10.1371/journal.pone.0032515; PMID: 22384267
   PubMedGoogle Scholar
• Oak S, Gilliam LK, Landin-Olsson M, Törn C, Kockum I, Pennington CR, et al. The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes. Proc Natl Acad Sci U S A 2008; 105:5471 - 6; http://dx.doi.org/10.1073/pnas.0800578105; PMID: 18367670
   PubMed Web of Science ®Google Scholar
• Ladjemi MZ, Chardes T, Corgnac S, Garambois V, Morisseau S, Robert B, et al. Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice. Breast Cancer Res 2011; 13:R17; http://dx.doi.org/10.1186/bcr2826; PMID: 21294885
   PubMed Web of Science ®Google Scholar
• Van Regenmortel MH. Basic research in HIV vaccinology is hampered by reductionist thinking. Front Immunol 2012; 3:194; http://dx.doi.org/10.3389/fimmu.2012.00194; PMID: 22787464
   PubMedGoogle Scholar
• Yang G, Holl TM, Liu Y, Li Y, Lu X, Nicely NI, et al. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med 2013; 210:241 - 56; http://dx.doi.org/10.1084/jem.20121977; PMID: 23359068
   PubMedGoogle Scholar
• Verkoczy L, Diaz M, Holl TM, Ouyang YB, Bouton-Verville H, Alam SM, et al. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci U S A 2010; 107:181 - 6; http://dx.doi.org/10.1073/pnas.0912914107; PMID: 20018688
   PubMed Web of Science ®Google Scholar